{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T17:31:54Z","timestamp":1748885514003},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s40121-015-0100-z","type":"journal-article","created":{"date-parts":[[2015,12,19]],"date-time":"2015-12-19T02:15:06Z","timestamp":1450491306000},"page":"81-87","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Dose Monitoring for Linezolid in a Patient with MRSA Pneumonia with Bacteremia in Diabetes Insipidus"],"prefix":"10.1007","volume":"5","author":[{"given":"Yoshihiko","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuuji","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Mizunuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Ishikura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,19]]},"reference":[{"issue":"4","key":"100_CR1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5588\/ijtld.11.0451","volume":"16","author":"H Cox","year":"2012","unstructured":"Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012;16(4):447\u201354.","journal-title":"Int J Tuberc Lung Dis."},{"key":"100_CR2","first-page":"87","volume":"5","author":"S Ager","year":"2012","unstructured":"Ager S, Gould K. Clinical update on linezolid in the treatment of gram-positive bacterial infections. Infect Drug Resist. 2012;5:87\u2013102.","journal-title":"Infect Drug Resist."},{"issue":"13","key":"100_CR3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","volume":"42","author":"DJ Stalker","year":"2003","unstructured":"Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003;42(13):1129\u201340.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"100_CR4","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/AAC.46.11.3484-3489.2002","volume":"46","author":"D Andes","year":"2002","unstructured":"Andes D, van Ogtrop ML, Peng J, Craig WA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother. 2002;46(11):3484\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"100_CR5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","volume":"42","author":"CR Rayner","year":"2003","unstructured":"Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42(15):1411\u201323.","journal-title":"Clin Pharmacokinet"},{"key":"100_CR6","doi-asserted-by":"crossref","unstructured":"MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother. 2003;51(Suppl 2):17ii\u201325.","DOI":"10.1093\/jac\/dkg248"},{"issue":"9","key":"100_CR7","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/bmc.3441","volume":"29","author":"S Hara","year":"2015","unstructured":"Hara S, Uchiyama M, Yoshinari M, et al. A simple high-performance liquid chromatography for the determination of linezolid in human plasma and saliva. Biomed Chromatogr. 2015;29(9):1428\u201331. doi: 10.1002\/bmc.3441 .","journal-title":"Biomed Chromatogr"},{"issue":"11","key":"100_CR8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","volume":"4","author":"K Yamaoka","year":"1981","unstructured":"Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn. 1981;4(11):879\u201385.","journal-title":"J Pharmacobiodyn"},{"issue":"6","key":"100_CR9","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","volume":"101","author":"RC Bone","year":"1992","unstructured":"Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The accp\/sccm consensus conference committee. American college of chest physicians\/society of critical care medicine. Chest. 1992;101(6):1644\u201355.","journal-title":"Chest"},{"issue":"4","key":"100_CR10","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/cc13984","volume":"18","author":"M Zoller","year":"2014","unstructured":"Zoller M, Maier B, Hornuss C, et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care. 2014;18(4):R148.","journal-title":"Crit Care"},{"issue":"4","key":"100_CR11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijantimicag.2013.06.015","volume":"42","author":"T Yagi","year":"2013","unstructured":"Yagi T, Naito T, Doi M, et al. Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients. Int J Antimicrob Agents. 2013;42(4):329\u201334.","journal-title":"Int J Antimicrob Agents."},{"issue":"1","key":"100_CR12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 2009;66(1):82\u201398.","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"100_CR13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","volume":"54","author":"RG Wunderink","year":"2012","unstructured":"Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54(5):621\u20139.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"100_CR14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0924-8579(01)00374-0","volume":"18","author":"H Onda","year":"2001","unstructured":"Onda H, Wagenlehner FM, Lehn N, Naber KG. In vitro activity of linezolid against gram-positive uropathogens of hospitalized patients with complicated urinary tract infections. Int J Antimicrob Agents. 2001;18(3):263\u20136.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"100_CR15","first-page":"1136","volume":"29","author":"JG Slatter","year":"2001","unstructured":"Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)c]linezolid to healthy human subjects. Drug Metab Dispos. 2001;29(8):1136\u201345.","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"100_CR16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00228-001-0380-y","volume":"57","author":"TL Sisson","year":"2002","unstructured":"Sisson TL, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol. 2002;57(11):793\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"100_CR17","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","volume":"46","author":"JE Conte Jr","year":"2002","unstructured":"Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002;46(5):1475\u201380.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-015-0100-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T15:02:50Z","timestamp":1567436570000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-015-0100-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,19]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["100"],"URL":"https:\/\/doi.org\/10.1007\/s40121-015-0100-z","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,19]]}}}